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INTRANASAL FENTANYL IN PEDIATRIC PATIENTS UNDERGOING BMT
Abstract
Title:

Intranasal Fentanyl in Pediatric Patients Undergoing Bilateral
Myringotomy and Tympanostomy Tube Placement

Background:

A 16 kg, 102 cm tall 26-month old male patient presented for
bilateral myringotomy and PE (pressure equalization) tube placement.
Bilateral myringotomy and PE tube placement is performed in more
than two million children annually in the United States, making it the
most common pediatric surgical procedure. Pain associated with this
procedure is subjective to each child’s individual experience. Rectal
Acetaminophen is a commonly used medication for this procedure,
however the literature suggests that when used alone it does not
provide adequate analgesia. An increasing number of anesthesia
providers are turning towards an alternative analgesic such as
intranasal Fentanyl (INF). Fentanyl is a lipophilic opioid agonist with
an ability to be rapidly absorbed via respiratory mucosa.

Purpose:

To conduct an extensive literature review of medications used in
children undergoing bilateral myringotomy and tube placement
(BMT), and to further determine which medication possesses the
most optimal analgesic effects.

Process:

A systematic literature review was conducted utilizing CINAHL,
Cochrane Library, Scopus and PubMed for research articles that
pertained to use of intranasal Fentanyl in pediatric patients
undergoing BMT. The reviewed literature was synthesized to develop
evidence-based recommendations for the use of intranasal Fentanyl in
pediatric patients undergoing BMT.

Results:

Administration of INF in healthy (ASA class 1 & 2) pediatric patients
has been shown to be safe, effective, and well tolerated with minimal
side effects when doses up to 2µg/kg are used. Use of INF in children
with multiple comorbidities, impaired respiratory control, and airway
obstruction should be evaluated on an individual basis.

Implications:

Informed decision-making process should be utilized on a case-bycase basis regarding the use of INF in pediatric patients undergoing
BMT. Anesthesia providers should be aware of the benefits and
undesirable side effects associated with INF administration, along
with the management of adverse effects. Whenever administering
opioids to pediatric patients undergoing BMT procedure, standard
monitors should be in place and frequent assessment of patient’s
condition should be evaluated on a continuous basis.

Keywords:

Pediatric patients, BMT, ear tubes, intranasal Fentanyl, INF.
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Background
In 1649, while cleaning an ear canal with an ear-spoon, Jean Riolan the Younger
accidentally pierced an eardrum in a patient complaining of hearing loss, which subsequently led
to the patient’s improved hearing (Brusis, & Luckhaupt, 1996). Myringotomy, a procedure
consisting of a surgical incision into the eardrum, has rapidly gained popularity amongst patients
with hearing disabilities. It took years to realize healing tendencies of an eardrum, and in 1845
Martell Frank first described a grommet, tube surgically implanted in the eardrum, made of gold
foil (Brusis, & Luckhaupt, 1996).
Bilateral myringotomy and pressure equalization (PE) tube placement is performed in
more than two million children annually in the United States (Hippard et al., 2012), making it the
most common pediatric surgical procedure (Galinkin et al., 2000). Myringotomy and PE tube
placement is a relatively short procedure lasting less than 10 to 15 minutes. Typically, the
anesthesia for this type of procedure consists of general anesthesia via mask ventilation without
the placement on an intravenous (IV) line. Due to absence of an IV, alternative routes for
medication administration may be necessary.
Inadequate pain control occurs when the pain experienced does not correlate to the
received pain management (Mudd, 2011). Current literature demonstrates inadequate and
unreliable pain control practices among pediatric patients (Mudd, 2011), where up to 87% of
children undergoing BMT need rescue analgesia (Pestieau et al. 2011). Furthermore,
retrospective studies show that up to 70% of pediatric patients undergoing BMT exhibit signs of
pain (Rampersad, Jimenez, Bradford, Seidel & Lynn, 2010).
The use of intranasal Fentanyl (INF) in the pediatric population is controversial amongst
anesthesia providers based on the perceived advantages and disadvantages of intranasal opioid
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administration. Some anesthesia providers are reluctant to use INF in children without
intravenous access due to the fear of potential undesirable side effects associated with opioid
administration.
The purpose of this paper was to conduct an extensive literature review of medications
used in children undergoing bilateral myringotomy and tube placement (BMT), and to further
determine which medication possesses the most optimal analgesic effects. The reviewed
literature analyzed current medication practices, advantages and disadvantages of those practices
along with current recommendations. Ultimately, strong evidence is presented demonstrating the
benefit of intranasal Fentanyl (INF) use in pediatric patients undergoing BMT procedure.
Various methods for optimal medications administration are presented and practice
recommendations are made in order to fully maximize the benefit of INF while minimizing any
potential side effects.
Case study
A 16 kg, 102 cm tall 26-month old male patient presented for bilateral myringotomy and
PE (pressure equalization) tube placement. The preoperative audiogram tympanogram showed
persistent left sided middle ear effusion and conductive hearing loss. The patient’s medical
history was obtained from the mother and was significant only for recurrent otitis media. The
patient had had five ear infections in the past eight months. According to patient’s mother, the
patient did not have any previous anesthesia history along with no family history of problems
with anesthesia. The patient’s medication profile included Albuterol 1.25mg/3ml as needed for
shortness of breath or wheezing. The last dose of Albuterol was two weeks prior to the scheduled
procedure. The patient had no known allergies. Preoperative physical examination and baseline
vital signs were unremarkable. Airway evaluation was limited due to patient’s level of
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cooperation. The patient was assigned an American Society of Anesthesiologists (ASA) physical
status 2. The patient had nothing by mouth for greater than eight hours.
Upon entering the operating room, an oxygen saturation monitor was applied to the
patient’s foot. Standard ASA monitors, precordial stethoscope and facemask were applied to the
patient. Sevoflurane was adjusted to 8% and Nitrous Oxide was adjusted to 50% in a mixture of
oxygen 4 L/min and Nitrous Oxide 4 L/min. Once the patient was anesthetized, 12.5mcg of
intranasal Fentanyl was administered bilaterally to each nare (total dose of 25mcg). Nitrous
Oxide was then turned off and general anesthesia was maintained with Sevoflurane 3.2% expired
concentration in a mixture of oxygen 2 L/min and air 2 L/min. Additionally, following the
induction, 240mg rectal Acetaminophen was placed by the operating room Registered Nurse.
Once the initial myringotomy incision was made there was a noticeable increase in the
patient’s heart rate from 95 to 110 beats per minute (bpm). After two minutes, the patient’s heart
rate decreased to 98 bpm, while the second myringotomy incision did not cause any additional
increase in heart rate. For the entire duration of the procedure the patient was masked without
difficulty while breathing spontaneously. As the second myringotomy incision was made,
Sevoflurane was turned off and patient was placed on 100% oxygen with oxygen flow of 8
L/minute.
Within minutes of the Sevoflurane being discontinued, the patient was awake, crying and
making purposeful movements. Oxygen saturation was 99% and the patient was transferred to
the Post Anesthesia Care Unit (PACU) with blow-by oxygen via mask. The patient remained
hemodynamically stable and encountered no complications throughout the entire surgical
procedure. During the postoperative visit, no signs of respiratory depression, hypoxia, nausea or
vomiting were noted.
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Discussion
Myringotomy & Pressure Equalization Tube Placement
Bilateral myringotomy and tympanostomy tube placement (BMT) is one of the most
common surgical procedures performed among pediatric patients in the United States (Hippard et
al., 2012 & Galinkin et al., 2000). Myringotomy and tympanostomy is indicated for patients with
chronic serous otitis media or recurrent acute otitis media (Jaffe, 2014). Chronic serous otitis
media is defined as a collection of fluid in the middle ear for greater than 3 months, while
recurrent otitis media is defined as a series of six or more episodes of otitis media over a 12month period (Jaffe, 2014).
BMT involves the patient being placed under general anesthesia typically without an
airway device such as a laryngeal mask airway (LMA) or endotracheal tube. An ear speculum is
inserted into the ear canal and any buildup of cerumen is removed. The tympanic membrane is
inspected for any abnormalities, and myringotomy incision is placed. Myringotomy is a medical
term indicating the placement of an incision in the tympanic membrane (Jaffe, 2014). In some
instances, any fluid present in the middle ear following the tympanic membrane incision is
suctioned. Once the surgical view of the middle ear is clear, a tympanostomy tube (pressure
equalization or PE tube) is positioned within the tympanic membrane. Antibiotic eardrops are
commonly inserted into the auditory canal. The patient’s head is then turned to the opposite side,
the surgeon and the microscope are repositioned, and the entire procedure is repeated on the
opposite ear (Jaffe, 2014).
Otitis Media
Acute otitis media (AOM) is an acute middle ear infection. The middle ear becomes
inflamed, and in some instance an effusion can develop. Otitis media with effusion (OME), also
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known as serous otitis media, indicates the presence of fluid in the middle ear without symptoms
of acute ear infection (Grossman & Porth, 2014). Otitis media with effusion is more common
than AOM and can develop spontaneously due to poor function of the Eustachian tubes
(Grossman & Porth, 2014). In some instances, OME can accompany a viral upper respiratory
tract infection or AOM. The pathophysiology behind acute otitis media (AOM) is believed to be
the dysfunction of the eustachian tube which allows fluid and bacteria to move from the
nasopharynx into the middle ear (Grossman & Porth, 2014). The incidence of AOM is more
prevalent in infants and young children possibly due to two factors: 1) infants and younger
children tend to have shorter, wider and more horizontal eustachian tubes compared to older
children and adults; and 2) infants tend to spend more time in the supine position allowing easier
spread of infection through the eustachian canal (Grossman & Porth, 2014).
Acute otitis media (AOM) can be either of bacterial or viral origin. The most common
bacterial infection associated with AOM is Haemophilus influenzae, with Streptococcus
pneumoniae being the second (Grossman & Porth, 2014). Since most cases of AOM proceed an
uncomplicated URI (upper respiratory infection), respiratory viruses can also be a leading cause
of AOM. Clinical manifestations of AOM include the following: acute onset of infants pulling
on their ears, fever greater than 39 Celsius, hearing loss, middle ear effusion and evidence of
middle ear inflammation (Grossman & Porth, 2014).
Otitis media with effusion (OME) is manifested with intact tympanic membranes and
accumulation of fluid in the middle ear (Grossman & Porth, 2014). OME does not present with
any signs or symptoms of infection, however individuals suffering from this condition can
present with hearing loss. The accumulation of fluid in the middle ear can last from less than 3
weeks to more than 3 months (Grossman & Porth, 2014). Many cases of OME resolve
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spontaneously, but recurrent episodes of OME occur as well. Persistent accumulation of fluid in
the middle ear from OME can result in decreased motility of the tympanic membrane and
impaired sound conduction (Grossman & Porth, 2014).
Myringotomy/ BMT & Pain Levels
Pain is a highly subjective and individualized experience. The amount of pain
experienced by pediatric patients undergoing BMT procedure is highly debatable, yet most
people agree that myringotomy is associated with a certain degree of discomfort. The tympanic
membrane is very sensitive (Dewhirst et al., 2014), and the incision caused during the
myringotomy can lead to patient discomfort. Despite the brief nature of the procedure, more than
50% of children experience significant pain following myringotomy and tube placement,
indicating the need for adequate analgesic treatment (Kokki, 2003).
A review of retrospective studies found that up to 70% of pediatric patients undergoing
BMT had either elevated heart rate, blood pressure, behavioral signs or complaints of pain
(Rampersad, Jimenez, Bradford, Seidel & Lynn, 2010). Pestieau et al. (2011) found rescue
analgesia to be necessary in up to 87% of children undergoing BMT. While the procedure itself
is very brief, children will often exhibit pain related behaviors (Finkel et al., 2001). The data
presented by Rampersad et al. (2010) and Pestieau et al. (2011) reveals the need for adequate
analgesia in patients undergoing myringotomy and tube placement. In the past, BMT was
performed without any intraoperative analgesia, which ultimately led to a high incidence of postoperative agitation, combativeness and a certain level of disorientation (Hippard et al., 2012).
Some of these undesirable postoperative behaviors were attributed to intraoperative Sevoflurane
use, while some of them were attributed to a lack of intraoperative pain management (Hippard et
al., 2012).
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It can be challenging to obtain a meaningful and accurate pain assessment in children
experiencing BMT pain (Bolton et al., 2002). Current literature notes “inadequate and
inconsistent pain control practices in pediatrics” (Mudd, 2011, p.316) despite the availability of
various analgesics and opioids. Pediatric patients receive only a fraction of the recommended
treatment options for pain management (MacLaren & Kain, 2008), likely due to the imprecise
nature of pain scales used amongst young children. Ideally, the pain medication administration
should be based on the child’s perception of pain. However, due to child’s lack of verbalization,
cognitive participation in the assessment of their pain, and pain localization the child might not
receive adequate analgesia (Derkay et al., 1998). The decision to administer pain medication is
commonly dependent on the health care provider’s ability to interpret the child’s expression of
pain (Knutsson, Tibbelin, & Von Unge, 2006).
Myringotomy is a painful procedure, and under ideal circumstances children undergoing
this procedure should receive anesthesia or analgesia (Belmont, 2004). A patient’s response to
injury can lead to enhanced catabolism, increased sympathetic activity, and can even lead to a
certain degree of immunosuppression (Mudd, 2011). Effective analgesia plays an important role
in the modification process of these physiological responses to injury, by minimizing the amount
of stress experienced by the body (Mudd, 2011). “The evidence surrounding inadequate pain
practices in children is substantial” (Mudd, 2011, p.321) and anesthesia professionals should do
everything in their power to improve this practice.
Myringotomy/ BMT & Alternative Medication Routes
There are numerous challenging aspects of intraoperative pain management during a
BMT. First, the procedure itself typically lasts only 10 to 15 minutes, therefore medications
administered intraoperatively need to have a very quick onset and short duration of action. A
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study published by Dewhirst et al. (2014) showed that BMT procedures, on average, lasted only
12 minutes, while a study published by Hippard et al. (2012) showed a mean procedure time of 7
minutes. Typically, an IV line is not placed in pediatric patients undergoing BMT. The
rationales for this non-intervention include additional surgical time delay and potential for
postoperative pediatric agitation related to IV presence. Furthermore, there are limited options
for short-acting and effective pain medications for pediatric patients experiencing acute pain.
Orally administered medications for pain management of BMT procedures are often
unpredictable with potentially altered absorption, slower onset, and prolonged duration of action.
Delayed gastric absorption might explain why orally administered Acetaminophen or Ibuprofen
one hour prior to induction failed to control post-operative pain behavior in pediatric patients
undergoing BMT (Hippard et al., 2012). All pediatric patients undergoing any type of procedure
or surgery typically have limited oral intake making the oral route of medication administration
undesirable. In contrast, rectal medications provide a more rapid onset, however the utilization of
this route is often undesirable. In many cases, pediatric patients undergoing BMT procedure
receive rectal Acetaminophen (Dewhirst et al., 2014). The main drawback with rectal
Acetaminophen is when administered alone, it does not provide sufficient analgesia (Dewhirst et
al., 2014). Furthermore, the absorption of rectal Acetaminophen is highly variable, with an onset
time of 45-60 minutes (Rampersad et al., 2010), while the peak effect is not reached for 2-3
hours following rectal administration (Finkel et al., 2001). Essentially, for rectal Acetaminophen
to be effective, it should be placed 45 minutes prior to the procedure, and some evidence
suggests that a larger dose (up to 60mg/kg rectally) than typically administered is needed to
achieve a therapeutic effect (Finkel et al., 2001). Rectal medication placement in an awake child
would create a certain amount of distress even before the actual procedure. The intramuscular
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route might be quick and easy, but it also poses a challenge due to delayed onset, long duration
of action, and pain associated with the injection site.
Some anesthesia providers might argue that intravenous (IV) route of medication
administration offers rapid delivery of rescue analgesia, however it can be time consuming to
start an IV in the operating room, especially when considering the total surgical time of BMT
procedure is only 10 minutes. Hippard et al. (2012) analyzed several studies to discover that IV
access did not provide any advantage in healthy children undergoing BMT, and in some
instances, patients without an IV access had less pain, faster recovery and higher parental
satisfaction scores. In addition to time constraint, IV placement in pediatric population is a
mastered skill, which creates an additional challenge to the anesthesia provider. Due to brief
nature of the procedure and no need of fluid replacement, children who undergo a BMT
procedure typically do not need an IV access (Finkel et al., 2001).
Intranasal Route
The intranasal (IN) route is currently gaining a certain level of popularity along with
some controversy. The intranasal route bypasses gastrointestinal first-pass metabolism, which
allows for rapid absorption into the systemic circulation via highly vascular nasal mucosa
(Corrigan, Wilson & Hampton, 2015). The avoidance of first pass metabolism results in greater
bioavailability of administered medications compared to orally and rectally administered
medications (Corrigan, Wilson & Hampton, 2015).
The respiratory mucosa contains a rich capillary network that receives more blood flow
per unit of tissue compared to brain, liver or muscles (Corrigan, Wilson & Hampton, 2015). The
cribriform plate of the skull, located in the upper portion of the nasal cavity, contains olfactory
cells that extend directly into the cranial cavity (Corrigan, Wilson & Hampton, 2015).
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Medications administered via intranasal route can be delivered directly to the cerebral spinal
fluid and brain via the olfactory nerve pathway, which is located in the olfactory mucosa
(Corrigan, Wilson & Hampton, 2015). Once the lipophilic drugs with low molecular weight
come in contact with the very vascular and large surface area of the nasal cavity, the absorbed
medication can produce serum concentrations similar to those achieved with intravenous
administration (Finkel et al., 2001). Intranasally administered medications can completely bypass
the difficult to penetrate blood-brain barrier, making this route of administration very effective
(Corrigan, Wilson & Hampton, 2015).
The intranasal route provides for a very quick, painless and a simple mode of medication
administration (Corrigan, Wilson & Hampton, 2015). In contrast, there are several disadvantages
of IN administration. Patients undergoing BMT can present with upper respiratory infections
(URI) and chronic rhinitis, which could potentially interfere with medication absorption and
efficacy (Dewhirst et al., 2014), however the presence of a URI does not seem to have any effect
on nasal absorption (Corrigan, Wilson & Hampton, 2015). Any type of nasal- septal abnormality
along with copious amount of nasal secretions of blood or mucus may present a barrier to
absorption by not allowing the medication to reach its site of action (Corrigan, Wilson &
Hampton, 2015).
Complications of Intranasal Administration
The most serious drawback of IN administration is the potential of laryngospasm.
Laryngospasm is a reflex leading to glottic closure as a result of noxious stimulation of the
superior laryngeal nerve (Nagelhout & Plaus, 2014). The laryngeal inlet closes by the actions of
supraglottic folds, true and false vocal cords, essentially leading to airway obstruction. The
management of laryngospasm consists of three essential steps: removal of noxious stimuli,
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increasing the depth of anesthetic and application of positive pressure ventilation in conjunction
with direct application of pressure toward the laryngospasm notch (Nagelhout & Plaus, 2014). If
none of the aforementioned interventions manage to break the laryngospasm, the last resort is the
administration of Succinylcholine, which causes vocal cord relaxation within 60 seconds
(Nagelhout & Plaus, 2014). The lack of IV access in most children undergoing BMT is not an
issue since Succinylcholine 4mg/kg can quickly and safely be administered via intramuscular
route into the deltoid muscle (Nagelhout & Plaus, 2014).
Despite the aforementioned drawbacks, current literature demonstrates that the presence
of any complications associated with IN medication administration is minimal compared to its
benefits (Galinkin et al., 2000). In a clinical trial conducted by Galinkin et al. (2000), 265
children, ASA class 1 or 2, received INF for their BMT procedure. The study found there were
no adverse effects of laryngospasm, postoperative respiratory depression, bronchospasm or
hypoxemia noted in any subjects. Recent research describes intranasal delivery of medications
as safe, effective and a convenient alternative to other routes of drug administration (Corrigan,
Wilson & Hampton, 2015).
Pharmacological Options for Intranasal Pain Management
The search still remains for an ideal analgesic for pediatric patients that would offer
simple and painless administration, adequate pain relief, rapid onset, and minimal adverse effects
(Mudd, 2011). Current literature review discovered the following two primary drugs being
administered via intranasal route for BMT procedures: Fentanyl and Dexmedetomidine.
Fentanyl
In 1960, Dr. Paul Janssen managed to synthesize the drug called Fentanyl, and we have
since seen its utilization increase steadily (Stanley, 1992). In the past, Fentanyl was only used as
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an analgesic in the operating room (OR). However, more recently Fentanyl has gained popularity
in the management of acute and chronic pain outside of the OR environment. Intravenous
Fentanyl is commonly administered to inpatient individuals experiencing acute pain, while
transdermal Fentanyl patches are increasingly being used in the management of chronic pain
(Grape, Schug, Lauer & Schug, 2010).
Lately, the intranasal route has been gaining popularity amongst healthcare providers for
the management of acute pain in the OR and emergency room department in adult and pediatric
patients. Fentanyl is currently the most widely investigated intranasal opioid in various clinical
and pharmacokinetic trials (Hansen, Mathiesen, Trautner & Dahl, 2012). In Australia, INF
administration is widely accepted and utilized by all major pediatric emergency room
departments (Crellin, Ling & Babl, 2010). Additionally, there are currently several clinical trials
testing the effectiveness of intranasal Fentanyl (INF) for the management of chronic cancer pain
and results thus far are very promising (Hansen, Mathiesen, Trautner & Dahl, 2012).
Fentanyl is an analgesic approximately 100 times more potent than Morphine (Stoelting
& Hillier, 2006) and its rapid onset and short duration of action make it very effective. Fentanyl
is a synthetic opioid agonist, which primarily exerts its action on mu receptors with some activity
seen on delta and kappa receptors (Stoelting & Hillier, 2006). All opioid receptors can be
classified into three main categories: mu, delta and kappa. Mu-1 receptors are primarily
responsible for analgesia and euphoria. Activation of Mu-2 receptors primarily causes respiratory
depression, physical dependence, constipation and some euphoria. Stimulation of delta receptors
primarily causes analgesia, however respiratory depression and minor constipation can be
observed as well. Lastly, kappa receptors are responsible for analgesia, sedation, dysphoria and
miosis (Stoelting & Hillier, 2006). Due to extensive first-pass metabolism, oral administration of
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Fentanyl is not an option; however due to its high lipophilicity and potency, Fentanyl can be
administered in a variety of routes (Grape, Schug, Lauer & Schug, 2010). The high lipophilicity
of Fentanyl allows for rapid diffusion into the central nervous system structures via the largely
lipophilic nasal mucosa, making the intranasal route of Fentanyl very effective (Corrigan, Wilson
& Hampton, 2015).
To date, most research on the use of intranasal Fentanyl has been done on the pediatric
population, and the data shows it to be safe and effective (Corrigan, Wilson & Hampton, 2015).
Intranasal Fentanyl (INF) offers an advantage of needle-free, rapid, and simple administration of
an opioid. The onset of INF is 6-8 minutes and the duration of analgesia is less than 1 hour,
making it a great choice for the management of acute pain (Hansen, Mathiesen, Trautner & Dahl,
2012), which is commonly seen in BMT procedures. Based upon randomized controlled trials, its
efficacy in the pediatric population has been proven to be very similar to intravenous Morphine
(Crellin, Ling & Babl, 2010).
A prospective, observational study conducted in the Emergency Room department by
Crellin, Ling and Babl (2010) analyzed the effectiveness of INF among children presenting with
upper limb injury. Even though this study contained only 36 children undergoing fracture
reductions, the main benefits of INF administration were clearly described. A total of 21 children
received adequate pain relief from INF administration, and no further analgesia was required.
The median dose of administered INF was 1.4µg/kg, and during this study no adverse effects
were observed. There were no hypotensive episodes, hypoxic events nor unarousable events,
which clearly demonstrates the safety profile of INF. The study concluded INF administration to
be safe and effective for children in the emergency room department presenting with acute
injuries.
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INF has been proven to be very effective and well tolerated with minimal side effects
when administered in doses of 1-2µg/kg (Mudd, 2011). INF administered at 2µg/kg results in a
significant decrease in postoperative agitation (Mudd, 2011 & Rampersad et al., 2010), which
can occur in up to 67% of children undergoing BMT with Sevoflurane alone (Finkel et al.,
2001). Galinkin et al. (2000) noted that 25-50% of children who undergo BMT emerge from
anesthesia with a certain degree of restlessness, disorientation, and inconsolability. Postoperative
agitation can be attributed to multiple factors such as: pain, delirium, agitation, parental
separation, hunger, thirst, etc. (Shi et al., 2015). Regardless of the cause, administration of
Fentanyl provides analgesia and sedation leading to a disruption in the patient’s agitation and
crying, and a subsequent decrease in the incidence of postoperative agitation (Shi et al., 2015).
Likewise, Galinkin et al. (2000) noted decreased incidence of severe agitation and decreased
heart rate in children receiving intranasal Fentanyl for BMT procedure.
Minimum Effective Concentration
The effectiveness of intranasal Fentanyl is closely associated with its absorption and
subsequent plasma concentration levels. Since it’s difficult to obtain subjective pain scores in the
pediatric population, it would be logical that blood concentration of Fentanyl would provide
insight on the correlation between the serum levels and efficacy of analgesia. Currently there are
no publications citing a minimum effective concentration of Fentanyl needed for adequate
analgesia in children. However, Galinkin et al. (2000) cited a study where adults receiving
Fentanyl patient-controlled analgesia following intra-abdominal procedures needed a minimum
effective concentration of 0.63±0.25ng/ml in order to achieve adequate analgesia. In its own
study, Galinkin et al. (2000) obtained 26 blood samples of children receiving 2µg/kg INF for
BMT procedure in order to determine their mean Fentanyl concentration. This study discovered
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that 10 minutes following the administration of INF 2mcg/kg, children undergoing BMT had
mean fentanyl concentrations of 0.8±0.28 and 34 minutes following the administration the
children had mean fentanyl concentration of 0.64±0.25ng/ml. Both of the obtained serum
Fentanyl concentrations indicated serum levels associated with adequate analgesia. There are
some limitations with this presented information such as the researchers compared the data
between the two different age groups. Furthermore, values presented for adults represented the
steady state concentration of Fentanyl, while values presented for children described their mean
Fentanyl concentration. Despite these limitations, the goal of this study was to provide a more
scientific explanation behind the effectiveness of INF. Galinkin et al. (2000) tried to demonstrate
INF effectiveness in children, and that INF administration will result in Fentanyl serum levels
that are associated with adequate analgesia in adults. Regardless of the evaluation method used,
whether it is serum level or behavior pain scale used in the PACU, current literature review
agrees on INF being able to provide adequate analgesia.
INF Administration Techniques
In the United States, the standard concentration of intravenously administered Fentanyl is
50mcg/ml. Since there is no standard formulation of Fentanyl specifically intended for intranasal
administration, the very same medication used for the intravenous administration is simply
administered into the nares (Mudd, 2011). It is important to note that nasal mucosa has a small
surface area, so when administering INF, smaller volumes of medication should be used in order
to avoid runoff into the nasopharynx (Grape, Schug, Lauer & Schug, 2010).
Intranasally administered Fentanyl should be dripped slowly into each nostril at least one
minute following the induction to ensure adequate anesthetic depth, with patient’s head turned to
the side (Finkel et al. 2001). The lateral head position ensures that the Fentanyl stays in contact
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with the lateral surface of the nasal cavity thus minimizing the medication runoff, while the
adequate anesthetic depth will minimize the potential of laryngospasm (Finkel et al., 2001).
Another potential solution to medication runoff into the posterior nasopharynx is the use of
mucosal atomizers when administering INF. The main advantage of mucosal atomizers is the
increased mucosal coverage, improved medication absorption, and decreased amount of
medication run off into the oropharynx and nasopharynx (Mudd, 2011). When utilizing a
mucosal atomization device, the provider should keep in mind that there is 0.1ml of dead space,
therefore an additional 0.1ml of medications should be drawn up to compensate for this dead
space (Corrigan, Wilson & Hampton, 2015). Minimizing the amount of drug reaching the
posterior nasopharynx would significantly decrease the potential of laryngospasm. Patients with
nasal congestion should have their nostrils suctioned prior to intranasal Fentanyl administration
(Galinkin et al., 2000). The best way to optimize the bioavailability of intranasally administered
medications is to minimize the barriers to absorption, minimize the volume by using a higher
concentration of medication if possible and to maximize the absorptive surface of the nasal
mucosa by using the device that maximizes drug dispersion while minimizing drug runoff
(Corrigan, Wilson & Hampton, 2015).
INF Side Effects
Fentanyl exhibits all common opioid related adverse effects such as pruritis, nausea and
vomiting, urinary retention, and respiratory depression. The most common side effect is nausea
and vomiting, while the most serious adverse effect of Fentanyl administration is the dosedependent respiratory depression (Grape, Schug, Lauer & Schug, 2010). Rampersad et al. (2010)
noted nausea and vomiting occurrence in 12% of individual receiving INF for BMT procedure,
yet when compared to other treatment groups this incidence did not have any statistical
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significance. Providers concerned with potential emesis should be aware of a correlation between
the peak serum concentration and incidence of emesis. When administered intravenously,
Fentanyl has the highest incidence of emesis at its peak serum concentration. As a result,
providers should be aware that intranasally administered Fentanyl has a peak serum
concentration occurring at 10 to 20 minutes post administration (Seith, Theophilos & Babl,
2012), therefore at that time, providers should be more vigilant of the potential side effects.
Likewise, the incidence of nausea appears to be correlated to the dose of administered
medication. Pestieau et al. (2011) noted that in children undergoing BMT, INF doses of 1mcg/kg
were associated with a 3.9% incidence rate of vomiting, while INF 2mcg/kg was associated with
12% incidence of vomiting. In contrast, Galinkin et al. (2000) found the incidence of
postoperative vomiting, hypoxemia and decreased respiratory rate not to be increased with the
administration of INF at 2µg/kg. Generally speaking, INF is considered to be safe with low
incidence of emesis due to a lack of histamine release (Seith, Theophilos & Babl, 2012).
Mudd (2011) stated Fentanyl’s most serious adverse effect of respiratory depression
being linked to higher doses exceeding 2µg/kg. Despite the lack of literature being able to link
the administration of INF to respiratory depression, anesthesia providers should be aware of
solutions to this potential problem. Naloxone, an opioid antagonist, is occasionally used to
reverse the undesirable side effects of opioid administration such as respiratory depression,
depressed mental status, uncontrollable pruritis, nausea, and vomiting. Prudent anesthesia
providers should be aware of the potential and undesirable side effects of INF and thus consider
regular and frequent assessments observing for presence of any adverse effects or signs of
inadequate analgesia. Intranasal Naloxone, which comes supplied as 1mg/ml, has been found to
be effective in the reversal of opioid induced respiratory depression when administered at a dose
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of 2mg (Corrigan, Wilson & Hampton, 2015), thus eliminating the need of intravenous access.
Intranasal Naloxone can be easily installed into the nostrils, however providers concerned with
higher volumes of medication reaching the posterior nasopharynx can also opt to use the
intramuscular route. The intramuscular Naloxone 0.8mg (supplied as 0.4mg/ml) is just as
effective as intranasal Naloxone, and it may provide a better clinical outcome compared to IN
Naloxone (Corrigan, Wilson & Hampton, 2015).
Dexmedetomidine
Dexmedetomidine is a highly selective Alpha-2 agonist that produces dose dependent
analgesia and sedation with only mild depression of ventilation (Stoelting & Hillier, 2006). The
administration of Dexmedetomidine provides multiple beneficial effects such as the following:
analgesia, sedation, improved quality of local anesthetics used for IV regional anesthesia,
attenuation of hemodynamic responses related to tracheal intubation, and decreased perioperative
requirements for opioids and inhaled anesthetics (Stoelting & Hillier, 2006). The preservation of
respirations while providing the sedative properties is the main benefit of Dexmedetomidine. The
general side effects of Dexmedetomidine are bradycardia and hypotension (Stoelting & Hillier,
2006), both of which can be detrimental in pediatric patients (Nagelhout & Plaus, 2014). When
administered intranasally, Dexmedetomidine is dosed 0.5-1 mcg/kg (Nagelhout & Plaus, 2014),
while some studies recommend a dose of 1- 2mcg/kg (Pestieau et al., 2011). The administration
of intranasal Dexmedetomidine is not associated with respiratory depression, however
Dexmedetomidine alone does not produce adequate sedation and analgesia (Hitt, Corcoran,
Michienzi, Creighton & Heard, 2014). Furthermore, unlike INF, which has rapid peak plasma
concentration within minutes of administration, IN Dexmedetomidine has a relatively slow onset
of 45 minutes and plasma peak effect at 90-150 minutes (Dewhirst et al., 2014). Anesthesia
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providers should be aware of the potential for bradycardia, which would necessitate prolonged
monitoring before and after the procedure (Pestieau et al., 2011).
A double-blinded, randomized controlled trial guided by Pestieau et al. (2011) examined
the effect of Dexmedetomidine in 160 children undergoing BMT. The trial randomized children
into four groups: the first group received IN Dexmedetomidine 1mcg/kg, the second group
received IN Dexmedetomidine 2mcg/kg, the third group received IN Fentanyl 2mcg/kg, and the
fourth group received placebo saline drops. The study had to be terminated early due to
significantly extended PACU stay of children receiving IN Dexmedetomidine 2mcg/kg. The
review of children receiving IN Fentanyl demonstrated adequate analgesia and reduced
postoperative agitation, while children receiving saline demonstrated higher pain scores and
higher requirements for analgesia in the PACU. The trial concluded that in children undergoing
BMT, higher doses of IN Dexmedetomidine were associated with significantly longer PACU
stays. Furthermore, in terms of pain, IN Dexmedetomidine was not superior to IN Fentanyl in
children undergoing BMT.
A study published by Dewhirst et al. (2014) compared the effectiveness of intranasal
Dexmedetomidine (1µg/kg) to intranasal Fentanyl (2µg/kg) in 100 ASA class 1 or 2 patients
ranging from 1 to 7.7 years, undergoing bilateral myringotomy and tympanoplasty tube
placement (BMT). In this randomized clinical trial, all patients received rectal Acetaminophen
40mg/kg, and the first 50 patients were additionally medicated with oral Midazolam. The study
analyzed four individual groups: intranasal (IN) Fentanyl alone, IN Fentanyl with Midazolam
premedication, IN Dexmedetomidine, and IN Dexmedetomidine with Midazolam premedication.
The study showed no clinically significant difference in terms of pain relief when IN Fentanyl
(2µg/kg) and IN Dexmedetomidine (1µg/kg) when compared alone. However, the study did
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conclude that intranasal Dexmedetomidine alone was associated with a significantly lower heart
rate among patients and prolonged PACU stays. In conclusion, the administration of IN
Dexmedetomidine did not offer any advantage over administration of IN Fentanyl.
Intranasal Fentanyl Versus Morphine
Morphine has long been the standard in which all other opioids are compared. Several
studies have compared Morphine to INF for BMT procedures. Mudd (2011) reviewed 12 studies
comparing the pain relief of INF to Morphine administration via oral (PO), intravenous (IV) and
intramuscular (IM) routes. One of these studies concluded that the children’s parents perceived
the intranasal route of Fentanyl administration to be significantly better to intramuscular
Morphine administration. Two studies noted decreased postoperative agitation in children
receiving INF, and three studies concluded that administration of INF provided a significantly
faster onset to analgesia compared to IV Morphine. One study showed a 3.9%-12% increased
incidence of vomiting in children receiving INF compared to placebo, however this finding was
not reported in any other studies. The remaining studies found comparable results between INF
and Morphine administration. No serious side effects of INF administration were noted in any of
the 12 analyzed studies.
The randomized, double-blinded, placebo controlled clinical trial described by Hippard et
al. (2012) analyzed the effectiveness of INF, IV Morphine and IM Morphine among 171
pediatric patients undergoing BMT. All 171 pediatric patients were randomized into 3 different
groups. Group 1 received INF 2µg/kg with IV and IM placebo saline, group 2 received IV
Morphine 0.1mg/kg with nasal and IM placebo, and group 3 received IM Morphine 0.1mg/kg
with nasal and IV placebo. All participating pediatric patients received general anesthesia with
Sevoflurane, Nitrous oxide and oxygen. The study concluded no difference in postoperative pain
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efficacy, PACU discharge time, side-effect profile or emergence delirium among children
receiving INF, IV and IM Morphine. Despite the already mentioned findings, the study
recommended the intramuscular (IM) route of medication administration. The explanation
behind the IM administration was the simplicity of administration, avoidance of potential time
delay associated with IV placement and avoidance of potential vocal cord irritation associated
with INF. In essence, this recommendation was based upon the risk of laryngospasm triggered by
INF administration, even though there were no incidents of laryngospasm noted in this study.
The review of literature concluded that INF was equivalent or superior to Morphine
administration via all routes (PO, IV, IM) for management of children’s acute pain (Mudd,
2011).
Alternative Analgesic Options to Intranasal Fentanyl
The various modalities available for pain management of pediatric patients undergoing
BMT include but are not limited to the following: oral and rectal Acetaminophen, Ibuprofen,
intranasal Fentanyl, intramuscular Ketorolac, intramuscular Morphine, topical 2% Lidocaine ear
drops and regional anesthesia. Voronov et al. (2008) conducted a double blinded, randomized
controlled trial (RTC) in 200 children undergoing myringotomy and tube placement. The goal of
this RTC was to compare the effectiveness of INF 2µg/kg to a nerve block of the auricular
branch of the Vagus (Nerve of Arnold) using 0.2ml of 0.25% Bupivacaine with 1: 200,000
Epinephrine. The auricular branch of the Vagus innervates the external auditory meatus and the
inferior portion of the tympanic membrane, an area where the incision for PE tube placement is
carried out. In order to perform this block, the tragus is everted and a 30G needle is advanced
until the cartilage is pierced. The needle is aspirated to rule out intravascular placement, followed
by injection of 0.2ml 0.25% Bupivacaine with 1:200 000 Epinephrine. In addition, both groups
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received 20mg/kg of rectal Acetaminophen suppository. The RTC concluded no difference in
pain scores between the administration of INF and the nerve block of the auricular branch of the
Vagus. Additionally, there was no difference between the two groups in incidence of nausea and
vomiting, wake-up time or discharge time (Voronov et al., 2008).
Rampersad et al. (2010) analyzed three different methods of analgesia for 228 children
undergoing BMT procedure. One group received only rectal Acetaminophen 40mg/kg, the
second group received intramuscular Ketorolac 1mg/kg in conjunction to rectal Acetaminophen
40mg/kg, and the third group received rectal Acetaminophen 40mg/kg along with INF 1mcg/kg.
All children were premedicated with oral Versed 0.5mg/kg and they all received inhalational
induction and maintenance with Sevoflurane, Oxygen and Nitrous Oxide. The use of
intramuscular (IM) Ketorolac in this randomized controlled trial implies that IM Ketorolac
1mg/kg could also be considered as an option for acute pain management in pediatric patients.
The drawback of intramuscular Ketorolac administration was bruising at the site of injection,
which was present in 4 out of 69 subjects and a slower onset time of 20-25 minutes. In current
practice, the use of IM Ketorolac in children is controversial and there is inconsistent data
regarding its pain efficacy in the pediatric population. Rampersad et al. (2010) primarily focused
on the incidence of emergence agitation among the three groups, yet they also noted no
significant difference in pain scores or side effects. It is worth mentioning that similar pain
scores were attributed to oral premedication with Midazolam. Due to premedication, the real
benefit of this study was not to compare the efficacy of the three different types of analgesia, but
instead to offer a possible alternative to INF use.
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Conclusion
The review of literature demonstrates a variety of pain management techniques currently
utilized in pediatric patients undergoing BMT procedures. The intranasal route offers a time
efficient, simple, fast and painless mode of medication delivery without the need for intravenous
access. Administration of INF in the pediatric population has been shown to be safe, effective,
and well tolerated with minimal side effects when doses up to 1-2µg/kg are used. Furthermore,
INF at 2µg/kg causes a significant decrease in postoperative agitation among pediatric
population, however, this higher dose (2mcg/kg) did demonstrate a potential for the increased
risk of respiratory depression. Use of INF in children with multiple comorbidities, impaired
respiratory control, and airway obstruction should be evaluated on an individual basis.
Anesthesia providers should be aware of the benefits and undesirable side effects
associated with INF administration, along with the management of adverse effects. When
administering INF, it is recommended to use mucosal atomization devices in order to minimize
the potential of laryngospasm. Undesirable side effects such as nausea and vomiting, are
associated with higher doses of INF, therefore anesthesia providers are advised to administer the
minimal amount of medication needed to achieve adequate analgesia. Standard monitors should
be in place when administering opioids to pediatric patients undergoing BMT and frequent
assessment of the patient’s condition should be evaluated on a continuous basis. Occurrence of
any unexpected side effects following the administration of INF should be treated with 0.8mg
intramuscular Naloxone. In conclusion, multiple benefits of INF administration outweigh its
potential drawbacks, therefore anesthesia providers should strongly consider the use of INF in
healthy pediatric patients undergoing BMT procedures.
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